Alzamend Neuro, Inc. Announces Results of 2026 Annual Shareholder Meeting: Key Proposals Approved, Including Reverse Stock Split Authorization

ATLANTA, GA – April 17, 2026 — Alzamend Neuro, Inc. (“Company”), a Nasdaq-listed (ALZN) clinical-stage biopharmaceutical company, has released the results of its annual meeting of shareholders held on April 17, 2026. The meeting included several proposals, all of which were approved by shareholders. These developments may have significant implications for the company’s future direction and could impact share value.

Key Highlights from the Annual Meeting

• Seven Directors Elected: Shareholders elected all seven director nominees to serve until the next annual meeting. This ensures continuity of leadership and the ongoing execution of the company’s strategic plans.
• Ratification of Independent Auditor: Haskell & White LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2026. This step supports transparency and ongoing financial integrity.
• Advisory Vote on Executive Compensation: Shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. This indicates shareholder confidence in management’s compensation practices.
• 2025 Stock Incentive Plan Approved: The Company’s 2025 Stock Incentive Plan was approved, allowing for new grants of equity to employees, directors, and officers. This is aimed at aligning management and employee interests with those of shareholders and retaining key talent.
• Nasdaq Listing Rule 5635(c) Equity Issuance: Shareholders approved the issuance of equity compensation to directors and executive officers, ensuring compliance with Nasdaq requirements and enabling the company to make incentive-based grants as needed.
• Authorization of a Reverse Stock Split: Critically, shareholders approved an amendment to the Company’s Certificate of Incorporation to authorize a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-2 and not more than 1-for-10. The exact ratio and timing will be determined by the board of directors at its discretion, to be implemented any time prior to April 16, 2027.

Details of the Reverse Stock Split Approval

The authorization for a reverse stock split is a potentially price-sensitive event. A reverse stock split reduces the number of shares outstanding and can increase the per-share market price. This corporate action is often used to regain compliance with Nasdaq’s minimum bid price requirements or to make shares more attractive to institutional investors.

The board now has the flexibility to implement a reverse split at a ratio between 1-for-2 and 1-for-10, giving them significant discretion to address market conditions and capital structure needs. The approval is valid until April 16, 2027, meaning the split could occur at any time within the next year, depending on board determination.

Shareholder Voting Results

The Company reported 3,804,741 shares of common stock outstanding and entitled to vote as of the record date. While the exact vote counts for director elections were not provided, approval rates for major proposals were as follows:

• Executive Compensation (Say-on-Pay): 276,241 votes in favor; 124,274 against; 13,057 abstain; 1,185,412 broker non-votes.
• 2025 Stock Incentive Plan: 265,482 in favor; 137,525 against; 10,565 abstain; 1,185,412 broker non-votes.
• Nasdaq Rule 5635(c) Equity Grant Approval: 264,877 in favor; 125,698 against; 10,162 abstain; 1,185,412 broker non-votes.

Other Important Information for Shareholders

• Emerging Growth Company: Alzamend Neuro, Inc. is classified as an emerging growth company under SEC rules, which allows the Company to take advantage of certain reduced reporting requirements.
• No Use of Extended Transition Period: The Company has not elected to use the extended transition period for complying with any new or revised accounting standards.
• Common Stock Details: The Company’s common stock, \$0.0001 par value, is traded on the Nasdaq Capital Market under the symbol ALZN.

Potential Share Price Impact

The approval to authorize a reverse stock split is the most potentially price-sensitive outcome of the meeting. Investors should closely monitor any communications from the Company regarding the implementation of the reverse split, as it may influence the share price and overall capital structure. While reverse splits do not change the fundamental value of the company, they can impact liquidity, compliance with exchange listing standards, and perception among institutional investors.

Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult with their financial advisors before making investment decisions. The company’s future actions, including the implementation of a reverse stock split, may significantly affect the price and trading of ALZN shares.

View Alzamend Neuro, Inc. Historical chart here